Phaseline

Targets › AVPR1A

AVPR1A (Vasopressin V1a receptor): drug programs, companies and trials

8 programs from 8 companies in 21 trials: 9 Phase 3, 5 Phase 4, 4 Phase 2, 3 Phase 1; Metabolic and endocrine, Genitourinary, Other; next expected readout Jan 2027.

Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. (UniProt, P37288)

Open in Phaseline: the race on AVPR1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TiohundraVasopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock …Jan 2027
Hamilton Health Sciences CorporationDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Chronic Kidney DiseasesFeb 2027
Assistance Publique - Hôpitaux de ParisDesmopressin Acetate
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3HyponatremiaDec 2027
Centre Hospitalier Universitaire DijonArgipressin
Vasopressin V1a receptor agonist
AVPR1APhase 3Patients With Norepinephrine-refractory Vasoplegic ShockJan 2029
Medical University of BialystokDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Kidney Biopsy–
Newleos TherapeuticsNTX-1472
V1a receptor antagonist
AVPR1APhase 2Social Anxiety Disorder (SAD)Jan 2027
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Desmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 2Cushing SyndromeOct 2028
PharmaINTerlipressin (PHIN-214)
Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent
AVPR1A, AVPR1B, AVPR2Phase 1Cirrhosis, Liver–

Conditions

Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Patients With Norepinephrine-refractory Vasoplegic Shock (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Cirrhosis, Liver (1) Social Anxiety Disorder (SAD) (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1)

Modalities

small molecule (8)

Companies

Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) Centre Hospitalier Universitaire Dijon (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Newleos Therapeutics (1) Tiohundra (1)

Related targets

AVPR2 (6) AVPR1B (6)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.